关于 2023 年度计提资产减值准备的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、计提资产减值准备情况概述 杭州博拓生物科技股份有限公司（以下简称"公司"）根据《企业会计准则》 及相关会计政策规定，为客观、公允地反映公司截至 2023 年 12 月 31 日的财务 状况及经营成果，公司对合并范围内截至 2023 年 12 月 31 日的各类资产进行了 减值测试，判断存在可能发生减值的迹象，本期计提的资产减值损失总额为 58,836,405.93 元。具体情况如下表所示： | | 项目 | 计提减值准备金额 | | --- | --- | --- | | 信用减值损失 | 应收账款坏账损失 | 3,673,983.59 | | | 其他应收款坏账损失 | -112,220.86 | | | 小计 | 3,561,762.73 | | 资产减值损失 | 存货跌价损失及合同履约成本减值损失 | 50,005,448.64 | | | 固定资产减值损失 | 5,269,194.56 | | | 小计 | 55,274 ...

国泰君安证券股份有限公司 关于杭州博拓生物科技股份有限公司 （一）首次公开发行股票募集资金情况 经中国证券监督管理委员会《关于同意杭州博拓生物科技股份有限公司首次 公开发行股票的批复》（证监许可[2021]2497号）同意，公司于2021年7月向社 会公众公开发行人民币普通股（A股）2,666.6667万股，每股发行价为人民币34.55 元，募集资金总额为人民币921,333,334.85元，扣除与发行费用有关的费用合计 人民币91,964,124.54元（不含税）后，公司实际募集资金净额为人民币 829,369,220.31元。上述募集资金已于2021年9月3日到位，到位情况经中汇会计 师事务所（特殊普通合伙）验证，并出具《验资报告》（中汇会验[2021]第6815 号）。 （二）募集资金使用及结余情况 截至2023年12月31日，公司募集资金使用及结余情况具体情况如下： 单位：万元 1 | 项目 | 金额 | | | --- | --- | --- | | 募集资金净额 | 82,936.92 | | | 减：以募集资金置换预先投入自筹资金的金额 | 12,378.20 | | | 减：对募集资金项目累计 ...

杭州博拓生物科技股份有限公司 内部控制审计报告 中国杭州市钱江新城新业路8号UDC时代大厦A座5-8层、12层、23层 Floors 5–8, 12 and 23, Block A, UDC Times Building, No. 8 Xinye Road, Qianjiang New City, Hangzhou Tel. 0571-88879999 Fax. 0571-88879000 www.zhcpa.cn 回 证明该审计报告是否由具有执业许可的会计师事务所出身 您可使用手机"扫一扫"或进入"注册会计 台 (http://acc.m 码:浙24N39L82UU 十六十二 内部控制具有固有局限性,存在不能防止和发现错报的可能性。此外,由于 情况的变化可能导致内部控制变得不恰当,或对控制政策和程序遵循的程度降低, 根据内部控制审计结果推测未来内部控制的有效性具有一定风险。 内部控制审计报告 中汇会审[2024]5357号 杭州博拓生物科技股份有限公司全体股东: 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求,我 们审计了杭州博拓生物科技股份有限公司(以下简称博拓生物公司)2023年12月3 ...

Financial Performance - The company's revenue for Q1 2024 reached ¥135,626,648.51, representing a year-on-year increase of 30.81%[5] - Net profit attributable to shareholders was ¥39,631,348.59, showing a significant growth of 233.05% compared to the same period last year[5] - The net profit after deducting non-recurring gains and losses was ¥39,439,732.29, reflecting a remarkable increase of 335.55%[5] - Basic earnings per share (EPS) stood at ¥0.38, which is an increase of 245.45% year-on-year[6] - Total operating revenue for Q1 2024 reached ¥135,626,648.51, a 30.8% increase from ¥103,685,805.87 in Q1 2023[23] - Net profit for Q1 2024 was ¥39,534,332.13, compared to ¥11,502,242.39 in Q1 2023, representing a significant increase of 243.5%[24] - Basic and diluted earnings per share for Q1 2024 were both ¥0.38, up from ¥0.11 in Q1 2023[25] - The company reported a total comprehensive income of ¥39,790,478.52 for Q1 2024, compared to ¥12,210,106.37 in Q1 2023, marking an increase of 226.5%[25] Research and Development - The total R&D investment amounted to ¥14,645,403.84, accounting for 10.80% of the revenue, an increase of 1.27 percentage points from the previous year[6] - Research and development expenses increased to ¥14,645,403.84 in Q1 2024, compared to ¥9,880,272.83 in Q1 2023, reflecting a 48.3% rise[23] Cash Flow and Liquidity - The net cash flow from operating activities was ¥56,524,065.34, with no applicable year-on-year comparison[5] - Cash flow from operating activities generated a net inflow of ¥56,524,065.34, a turnaround from a net outflow of ¥20,061,528.63 in the same period last year[28] - The net cash flow from investing activities was -158,167,545.39 CNY, indicating a significant outflow compared to the previous quarter's -9,292,153.48 CNY[29] - The total cash and cash equivalents at the end of the period were 1,765,712,542.46 CNY, down from 1,907,238,695.68 CNY at the beginning of the period[30] - The cash outflow from financing activities totaled 40,676,446.42 CNY, with a net cash flow from financing activities of -40,676,446.42 CNY[29] - The cash and cash equivalents decreased by 141,526,153.22 CNY during the quarter, reflecting a challenging cash flow environment[29] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,574,183,807.27, a slight decrease of 0.21% from the end of the previous year[6] - The company's cash and cash equivalents decreased to RMB 1,765,904,542.46 from RMB 1,907,430,695.68, reflecting a decline of approximately 7.4%[18] - Accounts receivable stood at RMB 60,565,920.29, down from RMB 61,888,543.95, indicating a decrease of about 2.1%[18] - The total current liabilities decreased to RMB 188,000,000.00 from RMB 189,000,000.00, showing a reduction of approximately 0.5%[19] - The total liabilities decreased to ¥153,172,237.72 from ¥158,820,879.74, indicating a reduction of approximately 3.9%[20] - The total equity attributable to shareholders increased slightly to ¥2,415,596,726.30 from ¥2,415,243,484.16, showing a marginal growth[20] Shareholder Information - The company reported a total of 7,673 common shareholders at the end of the reporting period[12] - The company reported a total of 10 major shareholders, with Hangzhou Tuokang Investment Co., Ltd. being the controlling shareholder[15] Share Repurchase - The company repurchased a total of 2,000,000 shares, representing 1.875% of the total share capital, with a total expenditure of RMB 54,273,421.33[15] - The highest repurchase price was RMB 33.48 per share, while the lowest was RMB 22.23 per share[15] Fixed Assets and Inventory - Fixed assets increased significantly to RMB 383,339,067.77 from RMB 220,573,094.57, reflecting an increase of about 73.7%[19] - Inventory decreased to RMB 81,513,475.04 from RMB 99,323,982.27, indicating a decline of approximately 17.9%[18] Management and Accounting - The company has not adopted new accounting standards for the current fiscal year, maintaining consistency in financial reporting[30] - The company’s management team includes Chen Yinlong as the responsible person and Yu Miaomiao as the accounting head, ensuring oversight of financial operations[30]

经核查独立董事王文明、应国清、王亮及其直系亲属和主要社会关系人 员的任职经历以及独立董事签署的相关自查文件,独立董事王文明、应国清、 王亮不存在《上市公司独立董事管理办法》第六条不得担任独立董事的情形, 在担任公司独立董事期间,独立董事已严格遵守中国证监会和上海证券交易 所的相关规定,确保有足够的时间和精力勤勉尽责地履行职责,作出独立判 断,不受公司主要股东、实际控制人或其他与公司存在利害关系的单位或个 人的影响。公司独立董事王文明、应国清、王亮符合《上市公司独立董事管 理办法》《上海证券交易所科创板上市公司自律监管指引第 1 号 -- 规范运 作》中对独立董事独立性的相关要求。 杭州博拓生物 「事会 月 25日 根据《上市公司独立董事管理办法》《上海证券交易所科创板上市公司 自律监管指引第 1 号 -- 规范运作》等要求,杭州博拓生物科技股份有限公 司(以下简称"公司")董事会,就公司在任独立董事王文明、应国清、王 亮的独立性情况进行评估并出具如下专项意见; 杭州博拓生物科技股份有限公司董事会 关于独立董事独立性情况的专项意见 ...

杭州博拓生物科技股份有限公司 2023年度独立董事述职报告 本人作为杭州博拓生物科技股份有限公司（以下简称"公司"）的独立董事， 在任职期间严格按照《中华人民共和国公司法》（以下简称"《公司法》"）《中 华人民共和国证券法》（以下简称"《证券法》"）《上市公司独立董事管理办 法》《上海证券交易所科创板股票上市规则》等法律法规及《公司章程》《独立 董事工作细则》《独立董事专门会议工作制度》的有关规定，在 2023 年度工作 中诚实、勤勉、独立地履行独立董事职责，积极出席相关会议，认真审议董事会 各项议案，对公司重大事项发表了独立、客观、公正的独立意见，切实维护公司 和全体股东的合法权益，促进公司规范运作，充分发挥了独立董事的独立作用。 现将本人 2023 年度独立董事述职情况报告如下： 一、独立董事的基本情况 （一） 个人工作履历、专业背景以及兼职情况 1965 年出生，中国国籍，无境外永久居留权，药物分析学博士学位，浙江工 业大学药学院教授、博士生导师。1990 年 9 月至 1993 年 12 月在杭州药厂生化 药物研究所任副所长；1993 年 12 月至今任浙江工业大学药学院教授、博士生导 师。现任浙江省 ...

杭州博拓生物科技股份有限公司 2023 年度审计报告 中国杭州市钱江新城新业路8号UDC时代大厦A座5-8层、12层、23层 Floors 5-8, 12 and 23. Block A. UDC Times Building. No. 8 Xinye Road, Qianjiang New City. Hangzhou Tel. 0571-88879999 Fax. 0571-88879000 www.zhcpa.cn 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mof.gov.cn）"进 报告编码:浙24PERN73XH 日 录 | | 页 次 | | --- | --- | | 一、审计报告 | 1-6 | | 二、财务报表 | 7-18 | | (一) 合并资产负债表 | 7-8 | | (二) 合并利润表 | 9 | | (三) 合并现金流量表 | 10 | | (四) 合并所有者权益变动表 | 11-12 | | (五) 母公司资产负债表 | 13-14 | | (六) 母公司利润表 | 15 | | (七) 母公司现金流量表 | 16 | | (八) 母公司所 ...

Financial Performance - The company's operating revenue for 2023 reached ¥1,901,143,935.01, representing a 76.75% increase compared to the previous year[24]. - The net profit attributable to shareholders of the listed company was ¥773,634,251.65, marking an 86.22% increase year-on-year[24]. - The net profit after deducting non-recurring gains and losses was ¥756,723,115.74, reflecting an increase of 89.50% compared to the previous year[24]. - Cash generated from operating activities amounted to ¥703,211,818.75, which is an 81.32% increase from the previous year[24]. - The net profit attributable to shareholders decreased by 86.22% compared to the previous year, amounting to ¥2,415,243,484.16[26]. - Basic and diluted earnings per share fell by 86.21% to ¥1.00, down from ¥7.25 in 2022[27]. - Revenue for the year dropped by 76.75%, primarily due to a significant decrease in demand for COVID-19 testing reagents[27]. - The weighted average return on equity decreased by 28.87 percentage points to 4.27%[27]. - Operating cash flow decreased by 81.32% year-on-year, reflecting reduced cash inflows from COVID-19 testing reagent sales[27]. - The total assets at the end of 2023 were ¥2,579,570,256.10, a decrease of 6.25% from the previous year[26]. Dividends and Share Repurchase - The company plans to distribute a cash dividend of 8.00 CNY per 10 shares, totaling 83,645,463.20 CNY, which accounts for 78.46% of the net profit attributable to shareholders for 2023[6]. - The total amount spent on share repurchase in 2023 was 14,760,652.50 CNY, leading to a combined total of 98,406,115.70 CNY for dividends and repurchases, representing 92.31% of the net profit attributable to shareholders[6]. Corporate Governance - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[9]. - The company has not violated any decision-making procedures for providing guarantees[9]. - The company has not experienced any situations where more than half of the directors could not guarantee the authenticity, accuracy, and completeness of the annual report[9]. - The company has not proposed any capital reserve transfer to increase share capital or bonus shares for the year[6]. - The company has not reported any special arrangements for corporate governance[7]. - The company’s governance practices align with the requirements set by the China Securities Regulatory Commission, with no major discrepancies noted[185]. - The company has established a complete governance structure in compliance with relevant laws and regulations, ensuring transparency and protection of stakeholder interests[185]. - The company held two shareholder meetings in 2023, with all proposed resolutions passed without any rejections[188]. Risk Factors and Challenges - The company emphasizes the importance of risk factors that may adversely affect its operations, as detailed in the management discussion and analysis section[4]. - The company's future plans and operational strategies are subject to risks and do not constitute a commitment to investors[8]. - The company faces risks related to new product development, including potential delays and regulatory challenges that could impact market competitiveness[123]. - The company is subject to stringent regulations under the new EU IVDR, which may require re-certification of products, posing risks to its market access[135]. - The company faces financial risks related to inventory depreciation and accounts receivable, particularly in the context of international trade dynamics[131][133]. Research and Development - Research and development expenses accounted for 18.20% of operating revenue, an increase of 12.51 percentage points from the previous year[27]. - Total R&D expenditure for the year was ¥80,475,253.93, a decrease of 25.63% compared to ¥108,208,922.33 in the previous year[97]. - The company has developed a range of monoclonal antibodies and detection methods, with several products in the industrialization phase[18]. - The company has established a stable R&D team, with a technical center in San Diego focusing on advanced biomedical engineering technologies[117]. - The company is committed to ongoing research and development to improve existing products and develop new diagnostic solutions[92]. Product Development and Market Expansion - The company is focused on expanding its market presence and enhancing its product offerings in the in vitro diagnostic sector[18]. - The company has plans for new product development and technological advancements to strengthen its competitive edge[18]. - The company is actively pursuing strategic partnerships and potential acquisitions to drive growth and innovation[18]. - The company aims to comply with international regulatory standards, including FDA and CE certifications, to facilitate market access[15]. - The company is expanding its product offerings in infectious disease testing, including tests for cholera, monkeypox, and various respiratory pathogens[50]. - The company launched a series of new drug abuse testing reagents, significantly improving sampling efficiency and user comfort with a rapid 30-second sampling time[41]. - The company has successfully completed 208 new certifications, including 203 international certifications and 5 domestic certifications, bringing the total to 694 certifications[43]. - The company is focusing on expanding its diagnostic product offerings in the in-vitro testing market[93]. Market Trends and Industry Insights - The global in vitro diagnostics (IVD) market is estimated to reach approximately $97.1 billion in 2023, with a projected compound annual growth rate (CAGR) of about 5.2% from 2023 to 2028[59]. - The point-of-care testing (POCT) market is expected to grow at a CAGR of 10.4% from 2022 to 2027, reaching a market size of $75.5 billion by 2027[59]. - The IVD and POCT industries are experiencing rapid growth due to the increasing prevalence of chronic and infectious diseases, as well as advancements in diagnostic technologies[59]. - The domestic POCT market in China is expected to exceed 26 billion yuan by 2026, with a growth rate consistently above 20%, significantly higher than the global average of around 10%[61]. - The aging population is projected to exceed 30% of the total population by 2035, leading to a surge in demand for chronic disease POCT testing, which is expected to expand rapidly[69]. Strategic Partnerships and Acquisitions - The company is exploring potential mergers and acquisitions to strengthen its market position and expand its product offerings in the diagnostics sector[88]. - The company has established strategic partnerships with multiple distributors in the international market, particularly in Europe and North America, to promote innovative testing solutions[44]. - The company completed a strategic acquisition of a competitor for $50 million, expected to enhance market share by 15%[194]. Management and Leadership - Chen Yinlong serves as the Executive Director and General Manager of Hangzhou Tuokang Investment Co., Ltd. since June 2015[197]. - Chen Yujie has been the CFO of Advin Biotech, Inc. since March 2019[198]. - The company has seen a significant turnover in its board members, with several new appointments in 2023[199]. - The management team is focused on strategic growth and market expansion through new product development and partnerships[198].

公司代码：688767 公司简称：博拓生物 杭州博拓生物科技股份有限公司 2023 年度内部控制评价报告 杭州博拓生物科技股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要求（以下简称企业内 部控制规范体系），结合本公司（以下简称公司）内部控制制度和评价办法，在内部控制日常监督和专 项监督的基础上，我们对公司2023年12月31日（内部控制评价报告基准日）的内部控制有效性进行了 评价。 一. 重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其有效性，并如实披露 内部控制评价报告是公司董事会的责任。监事会对董事会建立和实施内部控制进行监督。经理层负责 组织领导企业内部控制的日常运行。公司董事会、监事会及董事、监事、高级管理人员保证本报告内 容不存在任何虚假记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个别 及连带法律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及相关信息真实完整， 提高经营效率和效果，促进实现发展战略。由于内部控制存在的固有局限性，故仅能为实现上述目标 提供合理保证。此外，由于情况 ...

2023年度独立董事述职报告 本人作为杭州博拓生物科技股份有限公司（以下简称"公司"）的独立董事， 在任职期间严格按照《中华人民共和国公司法》（以下简称"《公司法》"）《中 华人民共和国证券法》（以下简称"《证券法》"）《上市公司独立董事管理办 法》《上海证券交易所科创板股票上市规则》等法律法规及《公司章程》《独立 董事工作细则》《独立董事专门会议工作制度》的有关规定，在 2023 年度工作 中诚实、勤勉、独立地履行独立董事职责，积极出席相关会议，认真审议董事会 各项议案，对公司重大事项发表了独立、客观、公正的独立意见，切实维护公司 和全体股东的合法权益，促进公司规范运作，充分发挥了独立董事的独立作用。 现将本人 2023 年度独立董事述职情况报告如下： 一、独立董事的基本情况 杭州博拓生物科技股份有限公司 （一） 个人工作履历、专业背景以及兼职情况 1964 年出生，中国国籍，无境外永久居留权，博士研究生学历，法学教授。 1990 年 7 月至 1998 年 7 月在曲阜师范大学先后任讲师、副教授，期间 1996 年 9 月至 1997 年 7 月在武汉大学访学；2001 年 7 月至今在浙江大学先后任副教 ...